학술논문
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
Document Type
Article
Author
Chappell, K.J.; Amarilla, A.A.; Modhiran, N.; Liang, B.; Wijesundara, D.K.; Lackenby, J.A.; Watterson, D.; Young, P.R.; Munro, T.P.; Mordant, F.L.; Hensen, L.; Zhang, W.; Nguyen, T.H.O.; Reading, P.C.; Kedzierska, K.; Subbarao, K.; Li, Z.; Ranasinghe, C.; Griffin, P.; Bennet, J.K.; Tran, M.H.; Tapley, P.; Barnes, J.
Source
In: eBioMedicine . (eBioMedicine, November 2023, 97)
Subject
Language
English
ISSN
23523964